The Australian Financial ReviewMesoblast wins Japanese approval for stem cell productThe Australian Financial ReviewTEMCELL is indicated as a treatment for children/adults with acute Graft Versus Host Disease (aGvHD) a severe complication arising from a hemopoietic stem cell transplant HSCT (a treatment for certain cancers which utilises stem cells derived from ...
http://blog.zandcell.com/mesoblast-wins-japanese-approval-for-stem-cell-product-the-australian-financial-review/
Inga kommentarer:
Skicka en kommentar